New York-based Sen-Jam Pharmaceutical has commenced a Phase 2 clinical trial in Australia for its hangover prevention therapy, SJP-001. This trial aims to evaluate SJP-001 as a potential FDA-approved treatment for hangover prevention, addressing a significant global health issue related to alcohol consumption.
Targeting Inflammation with SJP-001
SJP-001 is a combination drug containing naproxen and fexofenadine, designed to reduce inflammation caused by alcohol consumption. The therapy targets the inflammatory response triggered by alcohol, offering an alternative to simple hydration methods. Pre-clinical studies have indicated that SJP-001 can reduce both the severity and duration of hangover symptoms.
Jackie Iversen, Co-Founder and Chief Clinical Officer at Sen-Jam, stated, "Pre-clinical studies of SJP-001 have shown great promise in reducing both the severity and duration of morning-after symptoms. Our approach is based on international research identifying inflammation as the primary driver of these alcohol-related symptoms."
Innovative Funding Model
Sen-Jam has utilized crowdfunding and Fractional Royalty Rights (FRR) to fund the SJP-001 trial. Over 960 investors have supported the initiative, with 24% reinvesting, demonstrating confidence in the therapy's potential. This funding strategy allows Sen-Jam to maintain agility and deliver therapeutics effectively.
Jim Iversen, CEO of Sen-Jam Pharmaceutical, noted, "Our FRR offering allows everyday people to directly support innovation while creating an opportunity for financial returns. It also enables us to return capital to our investors soon after licensing deals are in place."
Broader Pipeline and Market Opportunities
Beyond hangover cures, Sen-Jam is developing a portfolio of anti-inflammatory drugs targeting multiple healthcare sectors, including arthritis, opioid withdrawal, viral respiratory infections, and COVID-19. The company is focusing on unmet needs in these multi-billion-dollar markets, with a total addressable market (TAM) estimated at $217 billion.
Sen-Jam is employing the FDA’s 505(B)2 regulatory pathway to accelerate drug development, leveraging existing safety data for small molecules. This approach aims to expedite the time to market for its therapies. The company holds formulation patents for SJP-001 in the US, Europe, Australia, Japan, Mexico, and South Africa, positioning it for global commercialization.
Addressing Health and Productivity
The development of SJP-001 aligns with efforts to enhance resilience and well-being for moderate drinkers. The therapy aims to protect cells and tissues from alcohol-related damage, supporting health and productivity.
According to Jim Iversen, "This innovative solution is about promoting human health and maximizing productivity by supporting individuals who choose to consume moderate levels of alcohol. Our focus is on enhancing well-being, fostering resilience, and empowering people to thrive in both personal and professional spheres."
